News ListWednesday November 28, 2007 A multi-center evaluation of WT1 assay in AML patients presented at the 49th Annual Meeting of the American Society of HematologyIPSOGEN, a leading provider of molecular diagnostic tests for the disease management of cancer patients, announced today that Dr. Cilloni will give an oral presentation of the results of a multi-center study performed within the... Category: Leukemia
 Tuesday November 20, 2007 Ipsogen launches the first quantitative JAK2 V617F mutation kitIPSOGEN, a leading molecular diagnostic company based in Franceand Connecticut, announces the immediate availability of its new JAK2 MutaQuant™ Kit, a research tool intended for the accurate quantification of JAK2 V617F... Category: Leukemia
Monday October 29, 2007 IPSOGEN facilities certified ISO13485 for IVDIPSOGEN, a leading molecular diagnostic company based in France and Connecticut, today announced that its headquarters in Marseille, France, have received ISO (International Standards Organization) 13485:2003.ISO 13485 is an... Category: Corporate
 Monday September 17, 2007 Ipsogen in-licenses NPM1 mutations’ technology from XenomicsIPSOGEN, a leading molecular diagnostic company based in France and Connecticut, today announced that it has signed a co-exclusive license agreement with XENOMICS (Pink Sheets: XNOM), a developer of next-generation medical DNA... Category: Leukemia
Monday September 10, 2007 Ipsogen grants Labcorp a license for JAK2 testing in the US.Marseille, France, September 10, 2007 - IPSOGEN, a leading provider of molecular diagnostic tests for the disease management of cancer patients, announced today the signing of an agreement with Laboratory Corporation of America®... Category: Leukemia
Monday September 10, 2007 Ipsogen announced today the signing of an agreement with Laboratory Corporation of America® Holdings under which LabCorp will offer a JAK2 molecular diagnostic assay in the USAIPSOGEN, a leading provider of molecular diagnostic tests for the disease management of cancer patients, announced today the signing of an agreement with Laboratory Corporation of America® Holdings (LabCorp®, NYSE: LH) under... Category: Leukemia
Tuesday September 04, 2007 Ipsogen and DNAVision enter in Agreement to offer In Vitro Diagnostic Tests for Breast CancerIPSOGEN, a leading molecular diagnostic company based in France and Connecticut, today announced that it has signed an agreement with DNAVision, a leading provider of pharmacogenomic services in Europe. With this agreement,... Tuesday August 28, 2007 Affymetrix and IPSOGEN Collaborate to Develop and Market In-Vitro Diagnostic Cancer TestsMARSEILLE, France and SANTA CLARA, Calif., August 28, 2007 – Affymetrix Inc. (Nasdaq: AFFX) and IPSOGEN, a leading molecular diagnostic company based in France and Connecticut, today announced that they have signed a Powered by... Category: Corporate
Tuesday August 28, 2007 Affymetrix and Ipsogen collaborate to develop and market in-vitro diagnostic cancer testsAffymetrix Inc. (Nasdaq: AFFX) and IPSOGEN, a leading molecular diagnostic company based in France and Connecticut, today announced that they have signed a Powered by Affymetrix™ (PbA) agreement. With this agreement, IPSOGEN... Category: Breast Cancer
 Tuesday August 14, 2007 Ipsogen grants an exclusive licence to Warnex for JAK2 testing in CANADAMarseille, France, August 14, 2007 – Ipsogen SAS. today announced the signature of an exclusive agreement with Warnex Inc. (TSX: WNX), a life sciences company devoted to protecting public health by providing laboratory services... Category: Leukemia
|
|
